For the Inventor, By the Inventor

Enter assignee name

Calgary, Canada

Zenith Epigenetics Corp.

USPTO Granted Patents = 24

% Expired Patents = 62.5

CIPO Patents = 3

EPO Patents = 10

Forward Citations = 233

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

John Frederick Quinn (20 out of 22 patents)

Bryan Cordell Duffy (19 out of 19 patents)

Shuang Liu (18 out of 67 patents)

4. Gregory Scott Martin (16 out of 18 patents)

5. Peter Ronald Young (16 out of 20 patents)

6. Ruifang Wang (15 out of 15 patents)

7. May Xiaowu Jiang (15 out of 20 patents)

8. Gregory Steven Wagner (15 out of 18 patents)

9. He Zhao (8 out of 34 patents)

10. Michael A Ellis (5 out of 19 patents)

11. Bruce Francis Molino (5 out of 41 patents)

12. David John Fairfax (3 out of 10 patents)

13. Vladimir Khlebnikov (2 out of 6 patents)

14. Samuel David Brown (2 out of 4 patents)

15. Olesya Kharenko (2 out of 2 patents)

24 patents: Sort by Forward Citations

1. 12145932 - Method of manufacturing a solid form of a BET bromodomain inhibitor (2024-11-19),

2. 11607405 - Combination therapy for the treatment of triple-negative breast cancer (2023-03-21),

3. 11446306 - Bicyclic bromodomain inhibitors (2022-09-20),

4. 11026926 - Substituted bicyclic compounds as bromodomain inhibitors (2021-06-08),

5. 10772892 - Bicyclic bromodomain inhibitors (2020-09-15),

6. 10710992 - Substituted pyridinones as bromodomain inhibitors (2020-07-14),

7. 10500209 - Quinazolinones as bromodomain inhibitors (2019-12-10),

8. 10363257 - Bicyclic bromodomain inhibitors (2019-07-30),

9. 10292968 - Substituted heterocycles as bromodomain inhibitors (2019-05-21),

10. 10231953 - Inhibitors of bromodomains (2019-03-19),

11. 10226451 - Substituted bicyclic compounds as bromodomain inhibitors (2019-03-12),

12. 10179125 - Substituted pyridines as bromodomain inhibitors (2019-01-15),

13. 10166215 - Substituted bicyclic compounds as bromodomain inhibitors (2019-01-01),

14. 10010556 - Bicyclic bromodomain inhibitors (2018-07-03),

15. 9861637 - Heterocyclic compounds as bromodomain inhibitors (2018-01-09),

Zenith Epigenetics Corp. is a biotechnology company based in Calgary, Canada, focused on the development of innovative therapies targeting epigenetic mechanisms. The organization specializes in research aimed at understanding and manipulating gene expression to treat various diseases, particularly cancer. By leveraging advanced scientific techniques, Zenith seeks to pioneer new treatment modalities that can significantly impact patient outcomes, positioning itself at the forefront of epigenetic research and therapeutic development.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Zenith Epigenetics Corp.

24 Patents

#44 in Calgary

#603 in Canada

#26,595 in the World

Calgary, Canada

Zenith Epigenetics Corp.

Forward Citations = 233

26 inventors:

John Frederick Quinn (20 out of 22 patents)

Bryan Cordell Duffy (19 out of 19 patents)

Shuang Liu (18 out of 67 patents)

4. Gregory Scott Martin (16 out of 18 patents)

5. Peter Ronald Young (16 out of 20 patents)

Please report any incorrect information to [email protected]

Loading…